Physician profile
Stephen W Coates
NPI 1487635066
$6,877.31
in general payments reported to CMS, 2019-2025
33 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $233 · 2021: $535 · 2022: $1,201 · 2023: $1,217 · 2024: $1,343 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860 · Education: $15.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.49 |
| Education | $15.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,454.63 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $822.50 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $699.46 | 2019-2025 | Entyvio |
| Allergan, INC. | $266.99 | 2019 | |
| Daiichi Sankyo INC. | $245.39 | 2019-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $218.78 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $205.32 | 2021-2023 | Dificid |
| Pfizer INC. | $193.67 | 2019-2022 | |
| Janssen Biotech, INC. | $188.12 | 2021-2024 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $161.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $150.89 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $150.85 | 2019-2025 | |
| Medtronic, INC. | $143.42 | 2023-2024 | Gi Genius, Bravo |
| Intercept Pharmaceuticals, INC. | $135.58 | 2019-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $126.11 | 2019-2025 | Rebyota |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $116.99 | 2022-2023 | Dupixent |
| Janssen Scientific Affairs, LLC | $89.82 | 2021 | |
| Alexion Pharmaceuticals, INC. | $85.13 | 2022 | |
| Celgene Corporation | $69.23 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $62.50 | 2020 | |
| Ethicon US, LLC | $57.88 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $42.04 | 2024 | Iqirvo, Bylvay |
| Ardelyx, INC. | $31.29 | 2025 | Ibsrela |
| Mauna Kea Technologies, INC. | $25.33 | 2019 | |
| Covidien LP | $23.35 | 2020 | |
| Aimmune Therapeutics, INC. | $21.05 | 2025 | Vowst |
| Organon LLC | $18.33 | 2023 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.19 | 2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2023 | Zeposia |
| Alfasigma USA, INC. | $14.43 | 2020 | |
| Dynavax Technologies Corporation | $13.48 | 2019 | |
| Cook Medical LLC | $11.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Coates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.